Management of Hyperlipidemia in Very High and Extreme Risk Patients in Croatia: an observational study of treatment patterns and lipid control
- PMID: 34285435
- PMCID: PMC8253072
- DOI: 10.20471/acc.2020.59.04.10
Management of Hyperlipidemia in Very High and Extreme Risk Patients in Croatia: an observational study of treatment patterns and lipid control
Abstract
Our observational study evaluated current management of elevated low-density lipoprotein cholesterol (LDL-C) in adult secondary prevention patients (all very high risk (VHR) by European guidelines) attending specialist clinics across Croatia. Data were collected retrospectively from patient records for the preceding 12 months. The subset judged to be at extreme risk (ER; American Association of Clinical Endocrinologists (AACE) criteria; n=48) were compared with the remaining patients (VHR group; n=41). All patients were receiving statins (75.6% VHR/81.3% ER at high-intensity), with only a minority receiving concomitant lipid-lowering treatment (7.3% VHR/16.7% ER). Median (Q1, Q3) LDL-C levels at the last visit were 1.9 (1.6, 2.4) mmol/L for VHR and 2.1 (1.5, 3.1) mmol/L for ER, with only 41.5% (95% CI 26.3-57.9) of VHR patients and 27.1% (15.3-41.9) of ER patients attaining their LDL-C targets (<1.8 mmol/L and <1.42 mmol/L, respectively). Thus, we found that a substantial proportion of VHR and ER secondary prevention patients being treated across Croatia had LDL-C levels exceeding the targets recommended in the European and newer AACE guidelines, but not all were receiving high-intensity statins. Identification of ER patients and their lipid patterns may help optimize usage of high-intensity statin treatment, alone or along with newer treatments, for better control of elevated LDL-C.
Keywords: Extreme risk patients; High-risk patients; Hyperlipidemia; Secondary prevention; Very high-risk patients.
Figures


Similar articles
-
Clinical Management of High and Very High Risk Patients with Hyperlipidaemia in Central and Eastern Europe: An Observational Study.Adv Ther. 2019 Mar;36(3):608-620. doi: 10.1007/s12325-019-0879-1. Epub 2019 Feb 13. Adv Ther. 2019. PMID: 30758746 Free PMC article.
-
[Hyperlipidemia management in Slovakia: observational study].Vnitr Lek. 2020 Winter;65(12):761-769. Vnitr Lek. 2020. PMID: 32013518 Czech.
-
Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.Curr Diab Rep. 2019 Nov 21;19(12):146. doi: 10.1007/s11892-019-1246-y. Curr Diab Rep. 2019. PMID: 31754844 Review.
-
Current lipid lowering treatment and attainment of LDL targets recommended by ESC/EAS guidelines in very high-risk patients with established atherosclerotic cardiovascular disease: Insights from the START registry.Int J Cardiol. 2020 Oct 1;316:229-235. doi: 10.1016/j.ijcard.2020.05.055. Epub 2020 May 26. Int J Cardiol. 2020. PMID: 32470532
-
2017 Taiwan lipid guidelines for high risk patients.J Formos Med Assoc. 2017 Apr;116(4):217-248. doi: 10.1016/j.jfma.2016.11.013. Epub 2017 Feb 24. J Formos Med Assoc. 2017. PMID: 28242176 Review.
Cited by
-
SUBCLINICAL HYPOTHYROIDISM AS A CONTRIBUTOR TO MACROVASCULAR COMPLICATIONS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS.Acta Clin Croat. 2022 Feb;60(3):483-495. doi: 10.20471/acc.2021.60.03.20. Acta Clin Croat. 2022. PMID: 35282484 Free PMC article.
-
[Dyslipidemia in high cardiovascular risk patients. Initial results from the REMEXDIS-IMSS study].Rev Med Inst Mex Seguro Soc. 2024 May 6;62(3):1-7. doi: 10.5281/zenodo.10998739. Rev Med Inst Mex Seguro Soc. 2024. PMID: 39528250 Free PMC article. Spanish.
References
-
- World Health Organization. Cardiovascular diseases. Fact sheet. Updated May 2017. http://www.who.int/mediacentre/factsheets/fs317/en/ In. 2017.
-
- Kannel WB. The Framingham Study: an epidemiological investigation of cardiovascular disease, Section 30. Some characteristics related to the incidence of cardiovascular disease and death: The Framingham Study. 18-year follow-up.Washington, D.C., Department of Health, Education, and Welfare, Publication No. (NIH) 74-599, 1974.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical